Magnesium Oxide Granules for Pharmaceutical Tableting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Magnesium oxide tablets face tableting problems such as capping, laminating, and quality defects due to heterogeneous structures, primarily caused by insufficient strength, which is exacerbated when using high-purity magnesium oxide as a raw material.
Innovation Solution
Magnesium oxide granules with a BET specific surface area of 7 to 50 m²/g and a CAA80/CAA40 ratio of 2 to 7 are used, preferably 10 to 45 m²/g and 2.2 to 6, to improve tablet strength and reduce tableting issues, while maintaining high purity and low heavy metal content.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If high-purity magnesium oxide is used as a raw material for tablets, then the purity and safety for pharmaceutical/food applications is improved, but tableting problems such as capping, laminating, and sticking occur more frequently
Solution Approach 1:
The patent applies parameter changes by controlling the calcination temperature of magnesium hydroxide to specifically produce magnesium oxide with a BET specific surface area of 7-50 m²/g. This parameter control resolves the contradiction by achieving both high purity (through controlled calcination) and reduced tableting problems (through optimized surface area that improves compressibility and tablet formation)
Solution Approach 2:
The patent creates a composite approach by combining magnesium oxide granules with specific physical properties (BET surface area 7-50 m²/g, CAA80/CAA40 ratio 2-7) with traditional tablet formulation components. This composite material strategy allows the use of high-purity magnesium oxide while the controlled granule properties prevent tableting defects
2Productivity
If compression molding is performed at high speed to increase productivity, then the production efficiency is improved, but stress and density distribution occurs in tablets resulting in heterogeneous inner structure
Solution Approach 1:
The patent applies preliminary action by pre-processing magnesium hydroxide through controlled calcination to create magnesium oxide granules with specific surface area and activity characteristics before tableting. This preliminary preparation ensures that the raw material has optimal properties for high-speed compression, allowing both high productivity and homogeneous tablet structure to be achieved
Data Source
AI summary
An object of the present invention is to provide magnesium oxide that can be preferably used for pharmaceutical applications or as a food additive. In particular, the object is to provide magnesium oxide granules with which tableting problems and quality defects can be reduced, and in more particular, to provide magnesium oxide granules with which tableting problems and quality defects can be reduced and which has less heavy metal incorporation and high purity of magnesium oxide. Provided are magnesium oxide granules for pharmaceutical applications or for addition to food having a BET specific surface area of 7 to 50 m2/g and CAA80/CAA40 of 2 to 7.